All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 24, 2022
Home » Topics » Deals and M&A

Deals and M&A
Deals and M&A RSS Feed RSS

Eye exam

Zhaoke licenses Asian rights to Visus presbyopia candidates in $130M deal

May 13, 2022
By Tamra Sami
No Comments
Visus Therapeutics Inc. has out-licensed phase III candidates Brimochol and Carbachol to Hong Kong’s Zhaoke Ophthalmology Ltd. to develop and commercialize its long-acting, presbyopia-correcting eye drops in greater China, South Korea and select Southeast Asian territories.
Read More
Oral medication

Orion picks up rights to Jemincare non-opioid pain drug in €15M deal

May 12, 2022
By Doris Yu
No Comments
Orion Corp. has secured exclusive global rights, outside China, to a non-opioid pain drug candidate from Jiangxi Jemincare Group Co. Ltd. The deal, for oral sodium channel inhibitor JMKX-000623, brought Jemincare €15 million (US$15.6 million) up front. In addition, Orion could pay the Chinese company development, commercialization, and sales milestones that Orion suggested could be “significant,” as well as tiered royalties of 8% to 15% based on future sales.
Read More

Taiho goes Pearl diving, brings up $405M Cullinan deal

May 12, 2022
By Randy Osborne
No Comments
Cullinan Oncology Inc.’s lead program deal with Otsuka Holdings Co. Ltd. subsidiary Taiho Pharmaceutical Co. Ltd. brings $275 million up front and the potential for as much as $130 million in regulatory milestone payments.
Read More
Handshake

Bridgebio bolsters itself with a $1.8B BMS deal

May 12, 2022
By Lee Landenberger
No Comments
Bridgebio Pharma Inc. is going back to the Bristol Myers Squibb Co. (BMS) well to restore its stalled momentum as the two companies have supercharged their July 2021 collaboration to develop an SHP2 inhibitor. Bridgebio could receive up to $905 million, including an up-front payment of $90 million plus $815 million in milestone and royalty payments, expected to be in the low- to midteens, in its new BMS collaboration to develop and commercialize BBP-398 in oncology.
Read More

Mooted reverse merger with Medsenic a lifeline for Bone Therapeutics

May 12, 2022
By Cormac Sheridan
No Comments
Bone Therapeutics SA has entered an exclusive three-month discussion period with Medsenic SAS, which could culminate in a reverse merger. The potential transaction represents a lifeline for the troubled Belgian cell therapy developer, which is running out of cash and which has been more or less abandoned by its shareholders.
Read More

Zhifei Lvzhu wins rights to whooping cough vaccine from Intravacc

May 11, 2022
By Doris Yu
No Comments
Beijing Zhifei Lvzhu Biopharmaceutical Co. Ltd. has picked up rights to a whooping cough vaccine candidate from Intravacc B.V. on undisclosed terms. Zhifei Lvzhu gained exclusive rights to develop and commercialize the vaccine in China, as well as nonexclusive rights in Africa, South America, and selected Asian countries. In turn, Intravacc is eligible to receive milestone and up-front payments plus royalties on net sales of the vaccine, should it reach market.
Read More

Juniper acquires infigratinib rights from Helsinn in emerging markets

May 10, 2022
By David Ho
No Comments
Juniper Biologics Pte. Ltd. has added another candidate to its pipeline in the space of less than a month. In the latest deal, the Singapore-based company inked an exclusive licensing agreement with Switzerland’s Helsinn Healthcare SA, gaining rights to develop and commercialize oncology drug infigratinib in Australia, New Zealand, Southeast Asia and certain markets in the Middle East and Africa.
Read More
China in red on globe

Hansoh wins greater China rights to oncology drug from Nikang in $218M deal

May 10, 2022
By Doris Yu
No Comments
Hansoh Pharmaceutical Group Co. Ltd. has acquired greater China rights to oncology candidate NKT-2152 from Nikang Therapeutics Inc. in a deal worth up to $218 million. Jiangsu, China-based Hansoh picked up exclusive rights to develop and commercialize the candidate in mainland China, Hong Kong, Macau and Taiwan. In turn, Nikang is eligible to receive $15 million up-front cash payment, as well as up to $203 million in potential development, regulatory and sales-based milestone payments, and tiered royalties.
Read More
Woman sleeping

Awake at the wheel: Jazz buys Sumitomo sleep disorder candidate in $1.14B deal

May 10, 2022
By Lee Landenberger
No Comments
Little more than a month after selling a narcolepsy drug from its portfolio, Jazz Pharmaceuticals plc has replaced it with another.
Read More
Brain illustration

CGRPs on the ascent in migraine, Pfizer paying $11.6B for Biohaven

May 10, 2022
By Randy Osborne
No Comments
Pfizer Inc. is taking over Biohaven Pharmaceutical Holding Co. Ltd. for $11.6 billion to bring aboard Nurtec ODT (rimegepant), the calcitonin gene-related peptide (CGRP) receptor antagonist first approved in February 2020 for acute migraine in adults with or without aura.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 135 136 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 23.
  • China U.S. deal

    Merck acquires global rights to cancer drug from Kelun in $1.4B deal

    BioWorld
    In a deal potentially worth more than $1.4 billion, Sichuan Kelun Pharmaceutical Co. Ltd. has out-licensed a large molecule drug in cancer to Merck & Co. Inc. for...
  • Lung cancer illustration

    Acea Pharma fails to win green light for abivertinib in China

    BioWorld
    Zhejiang Acea Pharmaceutical Co. Ltd. failed to obtain marketing approval from China’s NMPA for its third-generation EGFR tyrosine kinase inhibitor, abivertinib....
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing